cgoncology_cover.jpg
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09 mai 2024 08h00 HE | CG Oncology Inc.
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
cgoncology_cover.jpg
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
03 mai 2024 11h23 HE | CG Oncology Inc.
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
cgoncology_cover.jpg
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
24 avr. 2024 10h00 HE | CG Oncology Inc.
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
RactigenLogo.png
Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01
06 déc. 2023 07h00 HE | Ractigen Therapeutics
This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
TIP_link_300x300.jpg
Cell and Gene Therapy Manufacturing Services Market worth $26.72 Billion, Globally, by 2030 – Comprehensive Study by The Insight Partners
27 sept. 2023 10h12 HE | The Insight Partners
Pune, India, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cell & gene therapy (CGT) programs are rapidly advancing from research & development to clinical trials and commercial approval. Establishing...
Logo.png
Non-Muscle Invasive Bladder Cancer Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space - Protara, Janssen, Tyra, Pfizer, Roche, CG Oncology, ImmunityBio, Theralase, enGene, SURGE
08 juin 2023 13h00 HE | DelveInsight Business Research LLP
New York, USA, June 08, 2023 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Market is Expected to Showcase Significant Growth, Predicts DelveInsight | Key Companies in the Space - Protara,...
Figure 1
Theralase® Releases FY2022 Audited Financial Statements
26 avr. 2023 18h01 HE | Theralase Technologies Inc.
TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
theralase_logo_destroying_cancer.png
Theralase® Phase II NMIBC Clinical Study (Interim) Data Presented at the ASCO GU Cancer Symposium
23 févr. 2023 07h00 HE | Theralase Technologies Inc.
TORONTO, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
theralase_logo_destroying_cancer.png
Theralase Expands Intellectual Property Portfolio
28 juin 2022 07h00 HE | Theralase Technologies Inc.
TORONTO, June 28, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
theralase_logo_destroying_cancer.png
Theralase® Research - One of the Top 10 Most Downloaded Papers
24 juin 2022 07h00 HE | Theralase Technologies Inc.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...